Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy
| Autor: | M.E.L. van der Burg, A.M. Hoff, W. L. J. Van Putten, G. Stoter, C.J. Rodenburg, M. van Lent |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
medicine.medical_specialty Cyclophosphamide medicine.medical_treatment Phases of clinical research Salvage therapy Gastroenterology Carboplatin chemistry.chemical_compound Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Ovarian Neoplasms Cisplatin Chemotherapy business.industry Combination chemotherapy Middle Aged Prognosis medicine.disease Thrombocytopenia Surgery Oncology chemistry Drug Evaluation Female business Ovarian cancer medicine.drug |
| Zdroj: | European Journal of Cancer and Clinical Oncology. 27:248-250 |
| ISSN: | 0277-5379 |
| DOI: | 10.1016/0277-5379(91)90507-a |
| Popis: | 30 ovarian cancer patients with a relapse after prior cisplatin combination chemotherapy were treated in a phase II study with cyclophosphamide 100 mg/m 2 orally on days 1–7 and carboplatin 300 mg/m 2 intravenously on day 8. Treatment was well tolerated. The major side-effect was thrombocytopenia. 28 patients were evaluable for response. The response was 5 CRs (18%), 4 PRs (14%) 15 SDs (53%) and 4 PDs (14%), for an overall response rate of 32%. The overall progression-free survival lasted from 2 to 23 months, median 8 months. Overall survival ranged from 2 to 35+ months, median 12 months. Patients with a therapy-free interval of more than 1 year showed a higher response rate (46%) than patients with a shorter therapy-free interval (20%). It is concluded that platinum containing second-line chemotherapy, after treatment that already contained cisplatin, is only warranted to palliate symptoms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|